PLAT and multiple sclerosis: Blocking NMDARs with a monoclonal antibody (known as Glunomab) that selectively targets GluN1 inhibited tPA-induced leukocyte transmigration in vitro and halted the progression of neurological impairments in a mouse model of multiple sclerosis (i.e., autoimmune encephalomyelitis) in wild-type but not in tPA-deficient animals [149].